ANI Pharmaceuticals, Inc.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company dedicated to serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products.

Products & Services

Vancomycin Oral Solution:A pharmaceutical product for oral administration, likely used for treating specific infections.

Arimidex:A branded pharmaceutical product, commonly used in the treatment of breast cancer.

Purified Cortrophin Gel:An FDA-approved product for multiple indications, including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome.

Vancomycin Oral Solution:An oral solution for specific medical treatments, featured on the company website.

Arimidex:A medication product featured on the company website, likely for specific therapeutic use.

Specialties

Development of pharmaceutical products Manufacturing of pharmaceutical products Marketing of branded and generic prescription drugs Rare Disease Therapeutics Innovative Therapeutics Development Manufacturing and Commercialization of High-Quality Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Senior Notes T: - FT: Convertible Senior Notes	A: 316250000 MR: - FA: $316,250,000 FAN: 316250000	D: 2024-08-13 FD: 2024-08-13	-
2	RT: Convertible Senior Notes T: - FT: Convertible Senior Notes	A: 275000000 MR: - FA: 275,000,000 FAN: 275000000	D: 2024-08-07 FD: 2024-08-07	-
3	RT: Debt T: - FT: Debt	A: 250000000 MR: - FA: $250,000,000 FAN: 250000000	D: 2024-08-07 FD: 2024-08-07	-
4	RT: Public Offering T: - FT: Public Offering	A: 86250000 MR: - FA: approximately $86.25 million FAN: 86250000	D: 2023-05-16 FD: 2023-05-16	3 investors
5	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2023-05-12 FD: 2023-05-12	3 investors

Convertible Senior Notes Latest

2024-08-13

$316.2M

Convertible Senior Notes 2024-08-07

$275.0M

Debt 2024-08-07

$250.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Patrick D. Walsh

Director

T

Thomas J. Haughey

Chairman of the Board

N

Nikhil Lalwani

President and Chief Executive Officer

M

Matthew J. Leonard

Director

A

Antonio Pera

Director

M

Muthusamy "Samy" Shanmugam

Head of R&D and COO of NJ Operations

View 21 more team members with Pro

Unlock Full Team Directory

Recent News